Beta Thalassemia Pipeline Insight 2025 Report

Beta thalassemia is a genetic blood disorder that affects hemoglobin production, leading to anemia and other complications. The disorder is caused by mutations in the HBB gene, which codes for the beta-globin subunit of hemoglobin. There are several types of thalassemia, including beta thalassemia major, beta thalassemia intermedia, and beta thalassemia minor. The disease is more prevalent in certain populations, such as those of Mediterranean, Middle Eastern, and South Asian descent.

The Beta Thalassemia Pipeline Insight 2025 report provides comprehensive insights into the pipeline landscape for beta thalassemia treatment. The report highlights 22+ companies and 22+ pipeline drugs in development, including those in clinical and nonclinical stages. The report covers the pipeline drug profiles, including therapeutic assessment by product type, stage, route of administration, and molecule type. It also highlights inactive pipeline products and emerging therapies making headlines in the beta thalassemia pipeline.

Key Takeaways:

• On 14 October 2025, Vertex Pharmaceuticals Incorporated conducted a study in pediatric participants with TDT to evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
• On 14 October 2025, Regeneron Pharmaceuticals announced a study researching an experimental drug called REGN7999 (called "study drug") for non-transfusion-dependent beta-thalassemia patients.
• DelveInsight's Beta Thalassemia Pipeline report depicts a robust space with 22+ active players working to develop 22+ pipeline therapies for Beta Thalassemia treatment.
• The leading Beta Thalassemia Companies include CRISPR Therapeutics, CSL Vifor, Beam Therapeutics, EmeraMed, Fulcrum Therapeutics, Editas Medicine, EdiGene Inc, Silence Therapeutics, Phoenicia Biosciences, Shanghai BDgene, Disc Medicine, and others.
• Promising Beta Thalassemia Therapies include Vebeglogene Autotemcel, ACE-536, Luspatercept, HQK-1001, Deferitrin (GT56-252), Desferoxamine (DFO), Bitopertin, ICL670, and others.
• The Beta Thalassemia Pipeline report provides insights into the company's pipelines, including emerging drug candidates, competitive intelligence, and strategic partnerships.
• Beta Thalassemia Pipeline assessment by Route of Administration includes intravenous, subcutaneous, oral, and intramuscular products.
• Beta Thalassemia Pipeline assessment by Molecule type includes monoclonal antibody, small molecule, and peptide products.

Statistics:

• 22+ active players are working to develop 22+ pipeline therapies for Beta Thalassemia treatment.
• 22+ pipeline drugs are in development for Beta Thalassemia treatment.
• 14 October 2025: Vertex Pharmaceuticals Incorporated conducted a study in pediatric participants with TDT.
• 14 October 2025: Regeneron Pharmaceuticals announced a study researching an experimental drug called REGN7999 (called "study drug") for non-transfusion-dependent beta-thalassemia patients.
• Beta Thalassemia disease overview: Beta thalassemia is an inherited blood disorder that limits your body's ability to make beta-globin, an important protein needed to make hemoglobin and red blood cells.

Sources:

• www.delveinsight.com
• www.m2.co.uk
• www.abnewswire.com